Rodrigo G Salinas

Medico Reumatólogo (UBA). ASAS and GRAPPA
Reumatología del Hospital Italiano de La Plata. Diplomatura en Investigación:

[Rodrigo G Salinas @RodrigoGSalinas]

@reumacia Lo segundo que debemos asumir es que si consideramos la Enf Psoriasica como un continuado ya el paciente con simtomasMSK es un paciente más complejo, con más daño, con más carga de inflamación, ósea nos tocó bailar con la/el más fea/o

[The Journal of Rheumatology @jrheum]

Rheumatology Around the World 🌎

Establishing Centers of Excellence for Axial Spondyloarthritis in Latin America: Consensus Recommendations From the REAL-PANLAR Group

📖 https://t.co/8WFayugnYL
@RodrigoGSalinas @italianolaplata @PedroSantosMor5 @BiomabAR

#Spondyloarthritis

[Rodrigo G Salinas @RodrigoGSalinas]

It was a true honor to participate as a speaker at the @PPACMANgroup meeting in New York 🗽 , sharing our experience in the diagnosis and comprehensive evaluation of patients with psoriatic arthritis (#PsA).

[Rodrigo G Salinas @RodrigoGSalinas]

Gracias por compartir https://t.co/umUycEK2Yt

[The Lancet Rheumatology @TheLancetRheum]

NEW—Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis https://t.co/hB0SjEsylg @PanlarLeague

Free to read with registration on https://t.co/28wkm5ab69

[Rodrigo G Salinas @RodrigoGSalinas]

Proud to share our new paper on the pre-RA stage just published @seminarthrheum 📄

“Progression from seropositive arthralgia to rheumatoid arthritis: One-year predictors from a large cohort in the Reuma-Check program.”

[Rodrigo G Salinas @RodrigoGSalinas]

Honored to share that I’ve been invited as a speaker at the 9th PPACMAN Annual Meeting in New York City on December 18, 2025 🗽

👉 “Arthralgia with Risk of Progression to Psoriatic Arthritis: Lessons from Reuma-Check”
@PPACMANgroup #PsA

[Rodrigo G Salinas @RodrigoGSalinas]

An Honor be part @PanlarLeague

[The Lancet Rheumatology @TheLancetRheum]

NEW—Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis https://t.co/hB0SjEsylg @PanlarLeague

Free to read with registration on https://t.co/28wkm5ab69

[Rodrigo G Salinas @RodrigoGSalinas]

Thank you was an a real team work, @jrheum

[The Journal of Rheumatology @jrheum]

Now published in our new section: Rheumatology Around the World 🌍

Toward Harmonized Recommendations for Psoriatic Arthritis: A Comparative Viewpoint on Global Guidelines

📖 https://t.co/AnlBsnowZV
@Dr_AndreRibeiro @RodrigoGSalinas @HCPA_ @italianolaplata

#PsoriaticArthritis

[Rodrigo G Salinas @RodrigoGSalinas]

@psoriasis_hub Thank you

[Psoriasis and Psoriatic Arthritis Hub @psoriasis_hub]

CONGRESS | #ACR25 | PRESENTATION
Rodrigo Garcia-Salinas, Hospital Italiano La Plata, discusses findings from a prospective longitudinal cohort study investigating the therapeutic approach in patients with arthralgia at risk of progression to #PsA (ARP-PsA; N = 119).
A total of 44% of patients with ARP-PsA initiated treatment with NSAIDs (50%), csDMARD (48%), and corticosteroids (1%). Among these, 36% of patients met at least one high-risk criterion, with 60% receiving csDMARD (p = 0.04). At 1 year, 29% of patients developed PsA, of whom 62% were receiving csDMARD (p = 0.002).
Follow our live feed for more updates: https://t.co/8JxNPYaWZB
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#Psoriasis #PsoriaticArthritis #MedEd #MedicalCongress #RheumTwitter @italianolaplata

[ClinRheumatol @ClinRheumatol]

🔬 New study by Dr. Rodrigo García Salinas et al.
💡D2M-#axSpA affects ~ 9% of patients in real-world clinical practice.
🧩Clinical and structural predictors such as psoriasis, smoking and joint damage are associated with D2M.
🧪Articular US is a key tool for identifying high-risk patients.
📖https://t.co/Z1TqhdbIHn

[Rodrigo G Salinas @RodrigoGSalinas]

Toward Harmonized Recommendations for Psoriatic Arthritis: A Comparative Viewpoint on Global Guidelines https://t.co/hQonq4Mh7t

[ClinRheumatol @ClinRheumatol]

Late-Onset #AxSpA (lo-axSpA): A Distinct Subgroup?
👉https://t.co/Q4uBTTG1KL
📊 Key findings from the Reuma-check cohort:
✔️ 28% of axSpA cases started at ≥45 years.
✔️ More common in females (51%) & psoriasis (42%).
✔️ Lower NSAID response (52%) & HLA-B27 positivity (32%).
✔️ Shorter diagnosis delay (40 vs. 93 months) than early-onset axSpA
⚠️ lo-axSpA may require distinct diagnostic & treatment approaches.
https://t.co/doS6Y5oVy2

[Panlar @PanlarLeague]

🚀 ¡Un curso imperdible como apertura de PANLAR 2025! El SPARTAN–PANLAR axSpA Pre-congress Educational Course es la mejor manera de iniciar el evento reumatológico del año.

👉 Descubre todo lo que necesitas saber deslizando y prepárate para una experiencia educativa única.

🔥 ¿Qué tan desafiante crees que será este taller? Cuéntanos en los comentarios cuántos 🌶 le das y asegura tu lugar en este imperdible curso.

🌟 ¡Reserva tu cupo ahora y sé parte de PANLAR 2025!
https://t.co/5M8R3ta8gi
.
#PANLAR2025 #YoVoyAPANLAR

[Rodrigo G Salinas @RodrigoGSalinas]

@reumacia Bocadillo de Calamar…. Y unas pintas.

[WilsonBautistaM @WilsonBautistaM]

✅ Queremos compartir la noticia del registro #ESPALDA. Contamos con información de más de 400 pacientes con #Espondiloartrtitis Axial

✅Datos de países de #AmericaLatina para generar datos en la región

Gracias a investigadores locales @PanlarLeague @RodrigoGSalinas @FerSommer

[Rodrigo G Salinas @RodrigoGSalinas]

@mariaj_morenom @GRESSER_Espa @SEReumatologia @SMurcianaReuma Las menos son por axSpA,

[Rodrigo G Salinas @RodrigoGSalinas]

@reumacia Podemos usarla para cuando visitamos la hermosa Madrid